ROCO
3184
Market cap34mUSD
Oct 08, Last price
17.60TWD
1D
2.03%
1Q
11.75%
Jan 2017
-9.74%
IPO
-68.33%
Name
MicroBase Technology Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MicroBase Technology Corp., founded in 1997 and headquartered in Taoyuan City, Taiwan, specializes in providing critical drug administration solutions to patients and medical professionals throughout Taiwan. A key area of their expertise involves pioneering the development of non-silicon-based Micro-Electro-Mechanical Systems (MEMS) by leveraging LIGA technology. This sophisticated method facilitates the engineering and production of extremely small devices and micron-sized components. Their product offerings include "Pocket Air," an innovative inhalation device designed to assist individuals with respiratory conditions, and "PharMatrix," a line of micro-needle products tailored for convenient at-home application by women.
Key people
Tianlai Liu
General Manager · since 2021
Zhengxing Gao
Chief Financial Officer, Deputy General Manager · since 2012
Peiying Hong
Head of Finance & Accounting · since 2021
Yuren Chen
Director · since 2021
Yaoyu Du
Director · since 2021
Xin Li
Chairman of the Board · since 2021
Zhongjie Ren
Director · since 2024
Deli Chen
Independent Director · since 2021
Liancong Huang
Independent Director · since 2021
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||